Biphenyl Derivative Antimicrobial Adjuvant Patent Granted
Summary
USPTO granted Patent US12599575B2 to Korea Research Institute of Bioscience and Biotechnology for an antimicrobial adjuvant containing biphenyl derivative compounds as active ingredients. The patent covers technology that enhances sensitivity of gram-negative bacteria to polymyxin antibiotics, potentially reducing required dosages and associated side effects such as nephrotoxicity. The patent includes 14 claims and was filed on January 28, 2022 under Application No. 18275475.
What changed
USPTO granted Patent US12599575B2 for a biphenyl derivative compound designed as an antimicrobial adjuvant. The technology enhances sensitivity of gram-negative bacteria to polymyxin antibiotics, allowing for reduced antibiotic dosages while maintaining efficacy against bacterial proliferation.
For pharmaceutical manufacturers and healthcare providers, this patent establishes intellectual property protection for adjuvant technology that may offer improved treatment options for antibiotic-resistant infections. Inventors include Jun-Seob Kim, Choong-Min Ryu, and Seon-Yeong Kim, with CPC classifications spanning antimicrobial compositions (A61P 31/04) and related chemical compound categories.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antimicrobial adjuvant containing biphenyl derivative compound as active ingredient, and uses thereof
Grant US12599575B2 Kind: B2 Apr 14, 2026
Assignee
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors
Jun-Seob Kim, Choong-Min Ryu, Seon-Yeong Kim
Abstract
The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.
CPC Classifications
A61K 31/06 A61K 31/085 A61K 31/12 A61K 31/353 A61K 31/4035 A61K 38/12 A61K 2300/00 A61P 1/00 A61P 31/04 A61P 43/00 A01N 43/713 A01N 63/25 A01N 33/22 Y02A 50/30
Filing Date
2022-01-28
Application No.
18275475
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.